secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001437749-22-026608
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA maintains clinical hold on DM199 stroke trial; company to conduct additional IV stability study
--------------------------------------------------------------------------------

- FDA requires additional in-use in vitro stability study of IV administration of DM199 to resolve clinical hold on ReMEDy2 trial.
- Company to request Type A meeting with FDA in coming weeks for guidance on lifting hold.
- Cash and investments $36.1M as of Sep 30, 2022, down from $45.1M at Dec 31, 2021; runway into Q4 2024.
- R&D expense Q3 2022 $1.6M (down from $2.3M Q3 2021); G&A $1.5M (up from $1.1M).
- Net cash used in operating activities $8.7M for 9mo 2022, compared to $9.4M in 9mo 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922026608/0001437749-22-026608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922026608/dmtp20221108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer